The Great Masquerade: Identification of Clinically Relevant Clostridioides difficile Infections
Background: Despite clear guidance for appropriate testing of symptomatic patients for Clostridioides difficile testing (McDonald et al), the ideal testing methodology remains unresolved. Laboratories currently use different algorithms that incorporate enzyme immunoassay (EIA) testing for toxin, glu...
Gespeichert in:
Veröffentlicht in: | Infection control and hospital epidemiology 2020-10, Vol.41 (S1), p.s405-s405 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | s405 |
---|---|
container_issue | S1 |
container_start_page | s405 |
container_title | Infection control and hospital epidemiology |
container_volume | 41 |
creator | Sickbert-Bennett, Emily Stancill, Lisa DiBiase, Lauren Alby, Kevin Weber, David Jay |
description | Background:
Despite clear guidance for appropriate testing of symptomatic patients for
Clostridioides difficile
testing (McDonald et al), the ideal testing methodology remains unresolved. Laboratories currently use different algorithms that incorporate enzyme immunoassay (EIA) testing for toxin, glutamate dehydrogenase (GDH) antigen, and polymerase chain reaction (PCR) testing in combination or as a single test. At UNC Hospitals, a large academic hospital with nearly 1,000 beds in the ninth most populous state in the United States, patients are currently tested by an EIA test for toxin and GDH antigen first, and discordant toxin/GDH results are referred for PCR testing. Previous studies have demonstrated that detection of toxin by EIA is a better predictor of
C. difficile
infection (CDI) complications (Polage et al).
Methods:
We investigated all patients who were tested for
C. difficile
from July 2018 to June 2019. Within each testing methodology and result, we assessed the percentage of patients with at least 3 loose stools documented within a 24-hour period, percentage with a severe episode based on white blood cell (WBC) counts >15,000 cells/mL, or percentage with a serum creatinine level >1.5 mg/dL. Fisher-type confidence intervals were calculated for each proportion.
Results:
Patients positive for
C. difficile
by the EIA method had 66.9% appropriate loose stool documentation (95% CI, 57.4%–75.5%), whereas patients with EIA-indeterminate (toxin negative, GDH positive) and positive by only PCR had 49.7% appropriate loose stool documentation (95% CI, 42.7%–56.8%).
C. difficile
patients that tested negative had 48.1% appropriate loose stool documentation (95% CI, 46.0–50.2%). In addition, patients positive by the EIA method had nearly double the proportion of severe disease by WBC or creatinine criteria compared to patients who were either positive by PCR or who tested negative (Table 1).
Conclusions:
Patients positive for
C. difficile
by the EIA method were statistically more likely to meet criteria for loose stool documentation. There was no statistically significant difference between patients that tested positive only by PCR or who tested negative. The percentage of patients with severe episode criteria based on WBC or creatinine was nearly doubled between those who tested positive by EIA and PCR (20% vs 10%), although this finding was not statistically significant. The percentage with severe disease (WBC or creatinine) was nearly identical among pati |
doi_str_mv | 10.1017/ice.2020.1055 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2898301695</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2898301695</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1055-3108012890c2fc18475d3e52ddc62ec7f79982c8942f729a68058bc780d3ced3</originalsourceid><addsrcrecordid>eNotUMFKAzEUDKJgrR69BzxvfUma3cSbFK0LFUF68BZi8oIp625NtkL_3iz19JjHzLx5Q8gtgwUD1txHhwsOfEJSnpEZk1JXtRLLczIDpXWluPi4JFc57wCg0ZrNiNl-IV0ntCN9tfnngMl6fKCtx36MITo7xqGnQ6CrLvYFdt2RvmOHv7Yfy27IY4o-DtFjpj6Googd0rYP6CZlviYXwXYZb_7nnGyfn7arl2rztm5Xj5vKTWErwUAB40qD48ExtWykFyi5967m6JpQ0irulF7y0HBtawVSfbpGgRcOvZiTu5PtPg3liTya3XBIfbloiqkSwGotC6s6sVwack4YzD7Fb5uOhoGZKjSlQjNVaKZU4g8z92Rd</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2898301695</pqid></control><display><type>article</type><title>The Great Masquerade: Identification of Clinically Relevant Clostridioides difficile Infections</title><source>ProQuest Central Essentials</source><source>ProQuest Central (Alumni Edition)</source><source>ProQuest Central UK/Ireland</source><source>ProQuest Central</source><source>Cambridge University Press Journals Complete</source><creator>Sickbert-Bennett, Emily ; Stancill, Lisa ; DiBiase, Lauren ; Alby, Kevin ; Weber, David Jay</creator><creatorcontrib>Sickbert-Bennett, Emily ; Stancill, Lisa ; DiBiase, Lauren ; Alby, Kevin ; Weber, David Jay</creatorcontrib><description>Background:
Despite clear guidance for appropriate testing of symptomatic patients for
Clostridioides difficile
testing (McDonald et al), the ideal testing methodology remains unresolved. Laboratories currently use different algorithms that incorporate enzyme immunoassay (EIA) testing for toxin, glutamate dehydrogenase (GDH) antigen, and polymerase chain reaction (PCR) testing in combination or as a single test. At UNC Hospitals, a large academic hospital with nearly 1,000 beds in the ninth most populous state in the United States, patients are currently tested by an EIA test for toxin and GDH antigen first, and discordant toxin/GDH results are referred for PCR testing. Previous studies have demonstrated that detection of toxin by EIA is a better predictor of
C. difficile
infection (CDI) complications (Polage et al).
Methods:
We investigated all patients who were tested for
C. difficile
from July 2018 to June 2019. Within each testing methodology and result, we assessed the percentage of patients with at least 3 loose stools documented within a 24-hour period, percentage with a severe episode based on white blood cell (WBC) counts >15,000 cells/mL, or percentage with a serum creatinine level >1.5 mg/dL. Fisher-type confidence intervals were calculated for each proportion.
Results:
Patients positive for
C. difficile
by the EIA method had 66.9% appropriate loose stool documentation (95% CI, 57.4%–75.5%), whereas patients with EIA-indeterminate (toxin negative, GDH positive) and positive by only PCR had 49.7% appropriate loose stool documentation (95% CI, 42.7%–56.8%).
C. difficile
patients that tested negative had 48.1% appropriate loose stool documentation (95% CI, 46.0–50.2%). In addition, patients positive by the EIA method had nearly double the proportion of severe disease by WBC or creatinine criteria compared to patients who were either positive by PCR or who tested negative (Table 1).
Conclusions:
Patients positive for
C. difficile
by the EIA method were statistically more likely to meet criteria for loose stool documentation. There was no statistically significant difference between patients that tested positive only by PCR or who tested negative. The percentage of patients with severe episode criteria based on WBC or creatinine was nearly doubled between those who tested positive by EIA and PCR (20% vs 10%), although this finding was not statistically significant. The percentage with severe disease (WBC or creatinine) was nearly identical among patients who were positive by PCR and who tested negative. These findings demonstrate that documentation of loose stool is a more sensitive indicator of toxin detection than either clinical parameter, reinforcing the importance of stool documentation in evaluating patients for
C. difficile
testing.
Funding:
None
Disclosures:
None</description><identifier>ISSN: 0899-823X</identifier><identifier>EISSN: 1559-6834</identifier><identifier>DOI: 10.1017/ice.2020.1055</identifier><language>eng</language><publisher>Cambridge: Cambridge University Press</publisher><subject>Antigens ; Creatinine ; Disease control ; Documentation ; Toxins</subject><ispartof>Infection control and hospital epidemiology, 2020-10, Vol.41 (S1), p.s405-s405</ispartof><rights>2020 by The Society for Healthcare Epidemiology of America. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2898301695/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2898301695?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,21388,21389,23256,27924,27925,33530,33703,33744,43659,43787,43805,64385,64389,72469,74104,74283,74302</link.rule.ids></links><search><creatorcontrib>Sickbert-Bennett, Emily</creatorcontrib><creatorcontrib>Stancill, Lisa</creatorcontrib><creatorcontrib>DiBiase, Lauren</creatorcontrib><creatorcontrib>Alby, Kevin</creatorcontrib><creatorcontrib>Weber, David Jay</creatorcontrib><title>The Great Masquerade: Identification of Clinically Relevant Clostridioides difficile Infections</title><title>Infection control and hospital epidemiology</title><description>Background:
Despite clear guidance for appropriate testing of symptomatic patients for
Clostridioides difficile
testing (McDonald et al), the ideal testing methodology remains unresolved. Laboratories currently use different algorithms that incorporate enzyme immunoassay (EIA) testing for toxin, glutamate dehydrogenase (GDH) antigen, and polymerase chain reaction (PCR) testing in combination or as a single test. At UNC Hospitals, a large academic hospital with nearly 1,000 beds in the ninth most populous state in the United States, patients are currently tested by an EIA test for toxin and GDH antigen first, and discordant toxin/GDH results are referred for PCR testing. Previous studies have demonstrated that detection of toxin by EIA is a better predictor of
C. difficile
infection (CDI) complications (Polage et al).
Methods:
We investigated all patients who were tested for
C. difficile
from July 2018 to June 2019. Within each testing methodology and result, we assessed the percentage of patients with at least 3 loose stools documented within a 24-hour period, percentage with a severe episode based on white blood cell (WBC) counts >15,000 cells/mL, or percentage with a serum creatinine level >1.5 mg/dL. Fisher-type confidence intervals were calculated for each proportion.
Results:
Patients positive for
C. difficile
by the EIA method had 66.9% appropriate loose stool documentation (95% CI, 57.4%–75.5%), whereas patients with EIA-indeterminate (toxin negative, GDH positive) and positive by only PCR had 49.7% appropriate loose stool documentation (95% CI, 42.7%–56.8%).
C. difficile
patients that tested negative had 48.1% appropriate loose stool documentation (95% CI, 46.0–50.2%). In addition, patients positive by the EIA method had nearly double the proportion of severe disease by WBC or creatinine criteria compared to patients who were either positive by PCR or who tested negative (Table 1).
Conclusions:
Patients positive for
C. difficile
by the EIA method were statistically more likely to meet criteria for loose stool documentation. There was no statistically significant difference between patients that tested positive only by PCR or who tested negative. The percentage of patients with severe episode criteria based on WBC or creatinine was nearly doubled between those who tested positive by EIA and PCR (20% vs 10%), although this finding was not statistically significant. The percentage with severe disease (WBC or creatinine) was nearly identical among patients who were positive by PCR and who tested negative. These findings demonstrate that documentation of loose stool is a more sensitive indicator of toxin detection than either clinical parameter, reinforcing the importance of stool documentation in evaluating patients for
C. difficile
testing.
Funding:
None
Disclosures:
None</description><subject>Antigens</subject><subject>Creatinine</subject><subject>Disease control</subject><subject>Documentation</subject><subject>Toxins</subject><issn>0899-823X</issn><issn>1559-6834</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNotUMFKAzEUDKJgrR69BzxvfUma3cSbFK0LFUF68BZi8oIp625NtkL_3iz19JjHzLx5Q8gtgwUD1txHhwsOfEJSnpEZk1JXtRLLczIDpXWluPi4JFc57wCg0ZrNiNl-IV0ntCN9tfnngMl6fKCtx36MITo7xqGnQ6CrLvYFdt2RvmOHv7Yfy27IY4o-DtFjpj6Googd0rYP6CZlviYXwXYZb_7nnGyfn7arl2rztm5Xj5vKTWErwUAB40qD48ExtWykFyi5967m6JpQ0irulF7y0HBtawVSfbpGgRcOvZiTu5PtPg3liTya3XBIfbloiqkSwGotC6s6sVwack4YzD7Fb5uOhoGZKjSlQjNVaKZU4g8z92Rd</recordid><startdate>202010</startdate><enddate>202010</enddate><creator>Sickbert-Bennett, Emily</creator><creator>Stancill, Lisa</creator><creator>DiBiase, Lauren</creator><creator>Alby, Kevin</creator><creator>Weber, David Jay</creator><general>Cambridge University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>S0X</scope></search><sort><creationdate>202010</creationdate><title>The Great Masquerade: Identification of Clinically Relevant Clostridioides difficile Infections</title><author>Sickbert-Bennett, Emily ; Stancill, Lisa ; DiBiase, Lauren ; Alby, Kevin ; Weber, David Jay</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1055-3108012890c2fc18475d3e52ddc62ec7f79982c8942f729a68058bc780d3ced3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antigens</topic><topic>Creatinine</topic><topic>Disease control</topic><topic>Documentation</topic><topic>Toxins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sickbert-Bennett, Emily</creatorcontrib><creatorcontrib>Stancill, Lisa</creatorcontrib><creatorcontrib>DiBiase, Lauren</creatorcontrib><creatorcontrib>Alby, Kevin</creatorcontrib><creatorcontrib>Weber, David Jay</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>SIRS Editorial</collection><jtitle>Infection control and hospital epidemiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sickbert-Bennett, Emily</au><au>Stancill, Lisa</au><au>DiBiase, Lauren</au><au>Alby, Kevin</au><au>Weber, David Jay</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Great Masquerade: Identification of Clinically Relevant Clostridioides difficile Infections</atitle><jtitle>Infection control and hospital epidemiology</jtitle><date>2020-10</date><risdate>2020</risdate><volume>41</volume><issue>S1</issue><spage>s405</spage><epage>s405</epage><pages>s405-s405</pages><issn>0899-823X</issn><eissn>1559-6834</eissn><abstract>Background:
Despite clear guidance for appropriate testing of symptomatic patients for
Clostridioides difficile
testing (McDonald et al), the ideal testing methodology remains unresolved. Laboratories currently use different algorithms that incorporate enzyme immunoassay (EIA) testing for toxin, glutamate dehydrogenase (GDH) antigen, and polymerase chain reaction (PCR) testing in combination or as a single test. At UNC Hospitals, a large academic hospital with nearly 1,000 beds in the ninth most populous state in the United States, patients are currently tested by an EIA test for toxin and GDH antigen first, and discordant toxin/GDH results are referred for PCR testing. Previous studies have demonstrated that detection of toxin by EIA is a better predictor of
C. difficile
infection (CDI) complications (Polage et al).
Methods:
We investigated all patients who were tested for
C. difficile
from July 2018 to June 2019. Within each testing methodology and result, we assessed the percentage of patients with at least 3 loose stools documented within a 24-hour period, percentage with a severe episode based on white blood cell (WBC) counts >15,000 cells/mL, or percentage with a serum creatinine level >1.5 mg/dL. Fisher-type confidence intervals were calculated for each proportion.
Results:
Patients positive for
C. difficile
by the EIA method had 66.9% appropriate loose stool documentation (95% CI, 57.4%–75.5%), whereas patients with EIA-indeterminate (toxin negative, GDH positive) and positive by only PCR had 49.7% appropriate loose stool documentation (95% CI, 42.7%–56.8%).
C. difficile
patients that tested negative had 48.1% appropriate loose stool documentation (95% CI, 46.0–50.2%). In addition, patients positive by the EIA method had nearly double the proportion of severe disease by WBC or creatinine criteria compared to patients who were either positive by PCR or who tested negative (Table 1).
Conclusions:
Patients positive for
C. difficile
by the EIA method were statistically more likely to meet criteria for loose stool documentation. There was no statistically significant difference between patients that tested positive only by PCR or who tested negative. The percentage of patients with severe episode criteria based on WBC or creatinine was nearly doubled between those who tested positive by EIA and PCR (20% vs 10%), although this finding was not statistically significant. The percentage with severe disease (WBC or creatinine) was nearly identical among patients who were positive by PCR and who tested negative. These findings demonstrate that documentation of loose stool is a more sensitive indicator of toxin detection than either clinical parameter, reinforcing the importance of stool documentation in evaluating patients for
C. difficile
testing.
Funding:
None
Disclosures:
None</abstract><cop>Cambridge</cop><pub>Cambridge University Press</pub><doi>10.1017/ice.2020.1055</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0899-823X |
ispartof | Infection control and hospital epidemiology, 2020-10, Vol.41 (S1), p.s405-s405 |
issn | 0899-823X 1559-6834 |
language | eng |
recordid | cdi_proquest_journals_2898301695 |
source | ProQuest Central Essentials; ProQuest Central (Alumni Edition); ProQuest Central UK/Ireland; ProQuest Central; Cambridge University Press Journals Complete |
subjects | Antigens Creatinine Disease control Documentation Toxins |
title | The Great Masquerade: Identification of Clinically Relevant Clostridioides difficile Infections |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T05%3A01%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Great%20Masquerade:%20Identification%20of%20Clinically%20Relevant%20Clostridioides%20difficile%20Infections&rft.jtitle=Infection%20control%20and%20hospital%20epidemiology&rft.au=Sickbert-Bennett,%20Emily&rft.date=2020-10&rft.volume=41&rft.issue=S1&rft.spage=s405&rft.epage=s405&rft.pages=s405-s405&rft.issn=0899-823X&rft.eissn=1559-6834&rft_id=info:doi/10.1017/ice.2020.1055&rft_dat=%3Cproquest_cross%3E2898301695%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2898301695&rft_id=info:pmid/&rfr_iscdi=true |